Company / PP&E (Net)
Acadia Pharmaceuticals PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$7.5M
FY2025
5-year range
$4.2M / $8.0M
FY2021-FY2025
Trend
+78.2%
vs FY2024
Sector context
#102 of 193
Health Care
What the data says
At $8M, Acadia Pharmaceuticals's pp&e (net) ranks #102 of 193 in the Health Care sector. PP&E (Net) returned to growth in FY2025 after 4 years of decline, reaching $8M.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of -3.9%.
Improved from $5M to $8M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +7.6%
- 5-Year CAGR
- -3.9%
- 10-Year CAGR
- -
Sector benchmark
#102 of 193 in Health CareTop 53% of 193This company $7.5M Sector average $777.6M
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.9%, indicating a declining trend.
- In FY2025, pp&e (net) increased 78.2% year-over-year.
- Ranks #102 out of 193 companies in the Health Care sector.
- Peak pp&e (net) was recorded in FY2020.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.5M | +78.2% |
| FY2024 | $4.2M | -8.6% |
| FY2023 | $4.6M | -23.4% |
| FY2022 | $6.0M | -25.2% |
| FY2021 | $8.0M | -12.2% |
| FY2020 | $9.2M | +188.1% |
| FY2019 | $3.2M | -3.9% |
| FY2018 | $3.3M | +24.3% |
| FY2017 | $2.7M | -13.6% |
| FY2016 | $3.1M | +39.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026